$32.28
0.53% day before yesterday
Nasdaq, Dec 24, 09:42 pm CET
ISIN
US92790C1045
Symbol
VRDN

Viridian Therapeutics Inc Stock price

$32.28
+0.25 0.78% 1M
+17.62 120.19% 6M
+13.11 68.39% YTD
+12.97 67.17% 1Y
+2.70 9.13% 3Y
+14.65 83.10% 5Y
-147.72 82.07% 10Y
-2,012.97 98.42% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.17 0.53%
ISIN
US92790C1045
Symbol
VRDN
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$490.9m
Shares outstanding
82.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
90.5%
Return on Equity
-40.2%
ROCE
-62.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$70.8m | $79.6m
EBITDA
$-327.7m | $-296.4m
EBIT
$-328.1m | $-351.9m
Net Income
$-302.0m | $-347.8m
Free Cash Flow
$-326.3m
Growth (TTM | estimate)
Revenue
23,496.7% | 26,433.3%
EBITDA
-16.0% | 0.7%
EBIT
-15.9% | -17.7%
Net Income
-17.5% | -28.9%
Free Cash Flow
-65.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-462.9% | -372.4%
EBIT
-463.5%
Net
-426.6% | -437.0%
Free Cash Flow
-461.0%
More
EPS
$-3.7
FCF per Share
$-4.0
Short interest
10.0%
Employees
143
Rev per Employee
$0.0
Show more

Is Viridian Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Viridian Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Viridian Therapeutics Inc forecast:

21x Buy
88%
3x Hold
13%

Analyst Opinions

24 Analysts have issued a Viridian Therapeutics Inc forecast:

Buy
88%
Hold
13%

Financial data from Viridian Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
71 71
23,497% 23,497%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 77 77
2% 2%
109%
- Research and Development Expense 322 322
57% 57%
454%
-328 -328
16% 16%
-463%
- Depreciation and Amortization 0.46 0.46
19% 19%
1%
EBIT (Operating Income) EBIT -328 -328
16% 16%
-464%
Net Profit -302 -302
17% 17%
-427%

In millions USD.

Don't miss a Thing! We will send you all news about Viridian Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viridian Therapeutics Inc Stock News

Neutral
Business Wire
4 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for veligrotug for the treatment of thyroid eye disease...
Neutral
Business Wire
21 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock opt...
Neutral
Business Wire
about 2 months ago
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock opt...
More Viridian Therapeutics Inc News

Company Profile

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Head office United States
CEO Stephen Mahoney
Employees 143
Founded 2006
Website www.viridiantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today